NCT07354347 (DAN-ATP) is a NA clinical trial of Burst in Heart Disease, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT07354347?

NCT07354347 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT07354347?

Interventions in NCT07354347: Burst, Ramp.

What condition does NCT07354347 study?

NCT07354347 studies Heart Disease, Implantable Cardioverter Defibrillator (ICD), Heart Rhythm Disorders, Ventricular Tachyarrhythmias.

Is NCT07354347 still recruiting?

NCT07354347 is currently not yet recruiting. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT07354347: DAN-ATP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD

Not yet recruiting NA Last updated 27 January 2026

What this trial tests

NA trial testing Burst in Heart Disease in 3,980 participants. Not yet recruiting.

Timeline

1 February 2026

Primary endpoint
31 July 2041

31 July 2041

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3,980
Start date	1 February 2026
Primary completion	31 July 2041
Estimated completion	31 July 2041
Sites	1 location across Denmark

Drugs / interventions tested

Burst
Ramp

Conditions studied

Heart Disease — all drugs for Heart Disease →
Implantable Cardioverter Defibrillator (ICD) — all drugs for Implantable Cardioverter Defibrillator (ICD) →
Heart Rhythm Disorders — all drugs for Heart Rhythm Disorders →
Ventricular Tachyarrhythmias — all drugs for Ventricular Tachyarrhythmias →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Heart Disease or Implantable Cardioverter Defibrillator (ICD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pragmatic, two-group, cluster randomized trial designed to compare strategies for the Anti Tachycardia Pacing (ATP)-setting in the ventricular tachyarrhythmias (VT) zone when implanting a new implantable cardioverter defibrillator (ICD) in patients with heart disease in hospitals in Denmark. The strategies are: "Burst" or "Ramp" after 1. ATP (which is always burst) in VT zone. VT zone is defined between 180-249 (up to 269 in special cases) heartbeats per minute. The ICD will give either: Burst: The ICD is programmed to give ATP with 4 bursts. Or Ramp: The ICD is programmed to give ATP with 1 burst and 3 ramps. The participating hospitals will be assigned to one of two intervention strategies for periods of 4-months. The given intervention will follow the patient/ICD throughout the life time of the ICD, but with the possibility to reprogram at any time (intention to treat). It is calculated that the study needs a total of 398 events (second to fourth ATP), which is estimated to require 3980 implanted ICDs. The participants will be followed until the end of the ICD life, which is estimated to be around 10 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Disease

Currently open trials in the same condition.

NCT07380243 — Pathways to Prevention Food-is-Medicine Trial · NA · recruiting
NCT07126587 — Healthy Living Anson Study · NA · recruiting
NCT06927739 — Focused Orticumab Research for Treating Inflammation in Coronary Arteries · Phase 2 · recruiting
NCT06420960 — Diagnostic Efficacy of Connected WAtch ECG Versus External Holter ECG · NA · recruiting
NCT06896318 — Virtual Reality-Supported Cardiac Rehabilitation: Psychological, Functional, and Physiological Perspectives · NA · active not recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07354347 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07354347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing